勃林格殷格翰的思力华效果怎么样？

At present, bronchodilators have become the core drugs for the treatment of stable COPD. The existing long-acting inhaled bronchodilators include anticholinergics and β2 receptor agonists. It is a classic drug for the treatment of stable COPD. It was developed by Boehringer Ingelheim and is mainly used clinically for the treatment of chronic obstructive pulmonary disease (COPD).

Boehringer Ingelheim is the world's largest privately held pharmaceutical company, with 5 R&D centers around the world and more than 8,100 R&D and medical department employees. Boehringer Ingelheim was founded by Mr. Albert Boehringer in 1885. It has been adhering to the tradition of "innovation shows value and R&D drives growth" for hundreds of years.

How effective is Boehringer Ingelheim's Spliva?

In the human airway, Slivar has a high affinity with receptors and dissociates slowly from muscarinic M1 and M3 receptors, which can block cholinergic nerve-mediated contraction of bronchial smooth muscle for a long time. However, Slava dissociates from the muscarinic M2 receptor quite quickly, thus showing unique kinetic selectivity for M1 and M3 receptors.

In clinical trials, 298 patients with chronic obstructive pulmonary disease were included in a research trial and randomly divided into an observation group (149 cases) and a control group (149 cases). The observation group was treated with Silihua for 3 months, and the control group was treated with aminophylline for 3 months. The results showed that the lung function index of patients treated with Slihua was significantly better than that of the control group, and the difference was statistically significant.

In addition, it is not only used when experiencing breathing problems, normal use can also relieve persistent shortness of breath caused by the disease, helping to minimize the impact of the disease on daily life.

Recommended related hot articles: /newsDetail/88993.html